Abstract: Objectiv The aim of this study was to investigate the clinical efficacy of glucosteroid on blocking disease progress in patients with nucleos（t）ide analogue （NAs） withdrawal hepatitis （WH）. Methods 23 patients with NAsWH,who were diagnosed as in the tendency to hepatic failure owing to inappropriate NAs withdrawal,were recruited in this study,and 11 received conventional supporting therapy at base of enticavir antiviral treatment,and other 12 received hydrocortisone sodium pine succinate at dose of 100 mg daily and tapered as liver function improved. Results At the end of eight week observation,one patient in steroid-treated groupd,and three patients in the conventional treatment died because of progress to liver failure;the disease control time in the former was （22.4±9.4） d,significantly shorter than [（36.7±13.1） d,P<0.05] in the latter;at presentation,serum bilirubin,albumin,prothrombin time activities and model of end-stage liver disease scores in the two groups were not significantly different（P>0.05）,while at the end of eight-week observation,they were（20.8±11.6） μmol/L, （38.3±5.2） g/L,（68.9±11.2）% and（4.8±2.2） in the former,significantly different as compared to[（56.7±81.4） μmol/L,（34.7±23.1）g/L,（55.5±34.8）% and （10.9±2.6）,P<0.05] in the latter. ConclusionThe application of steroid for blocking disease progress to liver failure in patients with NAsWH might be efficacious,which needs further investigation.

Key words: Liver failure, Nucleos（t）ide analogues, Withdrawal hepatitis, Steroid, Therapy